AgingResearch.NewsJoin free

N-trans-feruloyltyramine

N-trans-feruloyltyramine has been studied in 1 paper since 2023: none in people yet, 1 in cells. No study of it in people or animals has been published yet. The newest paper, Dec 14, 2023: “Metabolite Profiling of Allium hookeri Leaves Using UHPLC-qTOF-MS/MS and the Senomorphic Activity of Phenolamides”.

Intervention

1 paper studies it1 findingUpdated

PubChemChEBI

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: Ministry of Science and ICT, South Korea and 3 more
  • Cells1

What did studies of N-trans-feruloyltyramine find?

1

Studies of N-trans-feruloyltyramine measured 1 outcome; the most studied are senescence-associated secretory phenotype (SASP) (1 study).

Senescence-associated secretory phenotype (SASP)

downin cells1

1 study

  1. N-trans-feruloyltyramine inhibits senescence-associated secretory phenotype (SASP) in cells.

    “N-trans-feruloyltyramine (7) to be the most potent compound, effectively inhibiting SASP markers and contributing to the senomorphic activities of A. hookeri.”

    Cells

    Metabolite Profiling of Allium hookeri Leaves Using UHPLC-qTOF-MS/MS and the Senomorphic Activity of Phenolamides

    Nutrients

More on Senescence-associated secretory phenotype (SASP)

Latest

Related